RE:RE:RE:ONC fair value is $152.36 CDN or $114USDFor comparison Merck announced full year 2022 worldwide sales at $59.3 billion, an increase of 22% from full year 2021.
During 2022, Keytruda sales climbed to $20.94 billion, up 22 percent from $17.19 billion in 2021. Lynparza sales were also up for the full year, hitting and exceeding the billion-dollar sales mark for the first time at $1.12 billion, a 13 percent increase versus $989 million the prior year.
Sales revenues from the sale of Keytruda represented for 1/3 (33%) of Merck's worldwide sales in 2022.
In 2022 Merck's outstanding shares totaled 2.54 Billion shares with Merck's share price peaking at US$115 in January 2023 giving Merck a a market cap of $292.1 Billion.
Sales of Keytruda represented approximately US$ 98 Billion of Merck's market cap.
Given that PD-(L)1inhibitor sales are expected to reach US$67 Billion in the next 4 years, the expected market cap increases of the those companies with immune checkpoint inhibitors would be approximately US$201 Billion by 2027, making this class of immunotherapy drugs a significant segment in the treatment of cancer, from a market perspective. (without the inclusion of ONCY's pelareorep)
And then considering that ONCY has the potential of increasing the effectiveness of PD-(L)1 inhibitors by 2-3x, those Big Pharma companies that currently possess an immune checkpoint inhibitor would appear significantly interested in acquiring ONCY (pelareorep) given pelareorep's ability to enhance checkpoint inhibitor efficacy while expanding the PD-(L)1 market in the process. Any Big Pharma company seeking to differentiate their PD-(L)1 drugs from the competition while gaining a bigger percentage of the expanded PD-(L)1 market, would certainly be interested in acquiring ONCY for the US$9-10 Billion that the above "fair value" per share figure represents.